JP2017507131A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507131A5 JP2017507131A5 JP2016550573A JP2016550573A JP2017507131A5 JP 2017507131 A5 JP2017507131 A5 JP 2017507131A5 JP 2016550573 A JP2016550573 A JP 2016550573A JP 2016550573 A JP2016550573 A JP 2016550573A JP 2017507131 A5 JP2017507131 A5 JP 2017507131A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antibody agent
- agent according
- residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461938605P | 2014-02-11 | 2014-02-11 | |
| US61/938,605 | 2014-02-11 | ||
| PCT/US2015/015510 WO2015123362A1 (en) | 2014-02-11 | 2015-02-11 | Novel full spectrum anti-dengue antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507131A JP2017507131A (ja) | 2017-03-16 |
| JP2017507131A5 true JP2017507131A5 (enExample) | 2018-03-22 |
| JP6707455B2 JP6707455B2 (ja) | 2020-06-10 |
Family
ID=53800606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550573A Active JP6707455B2 (ja) | 2014-02-11 | 2015-02-11 | 新規フルスペクトル抗デング抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9902764B2 (enExample) |
| EP (1) | EP3104888A4 (enExample) |
| JP (1) | JP6707455B2 (enExample) |
| KR (1) | KR20160119806A (enExample) |
| CN (1) | CN106413749B (enExample) |
| AU (1) | AU2015217149B2 (enExample) |
| BR (1) | BR112016017764A2 (enExample) |
| CA (1) | CA2938495A1 (enExample) |
| IL (1) | IL246788A0 (enExample) |
| MX (1) | MX375402B (enExample) |
| SG (2) | SG10201807826XA (enExample) |
| WO (1) | WO2015123362A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3059246T3 (en) | 2007-09-26 | 2018-10-01 | Chugai Pharmaceutical Co Ltd | Modified constant region of an antibody |
| KR102165384B1 (ko) | 2012-08-07 | 2020-10-16 | 메사추세츠 인스티튜트 오브 테크놀로지 | 항-뎅기 바이러스 항체 및 이들의 용도 |
| CA3212977A1 (en) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
| CA2938495A1 (en) * | 2014-02-11 | 2015-08-20 | Massachusetts Institute Of Technology | Full spectrum anti-dengue antibody |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| CN109311986A (zh) | 2016-03-25 | 2019-02-05 | 威特拉公司 | 登革热病毒抗体分子的制剂 |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| JP2022008719A (ja) * | 2016-11-23 | 2022-01-14 | セルヴァス エーアイ インコーポレイテッド | 疾患発症予測方法及び装置 |
| US20200131251A1 (en) | 2016-12-23 | 2020-04-30 | Serum Institute Of India Private Limited | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
| IL277375B2 (en) | 2018-03-15 | 2025-08-01 | Chugai Pharmaceutical Co Ltd | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
| DK0804070T3 (da) | 1993-03-09 | 2000-08-07 | Genzyme Corp | Fremgangsmåde til isolering af proteiner fra mælk |
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| JPH07299655A (ja) | 1994-04-30 | 1995-11-14 | Aisin Seiki Co Ltd | 内スプライン歯面仕上機 |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| CN1305905C (zh) | 2002-03-22 | 2007-03-21 | Aprogen株式会社 | 人源化抗体及其制备方法 |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| DK1556477T3 (en) | 2002-11-01 | 2017-10-23 | Glaxosmithkline Biologicals Sa | Process for drying |
| CA2894300A1 (en) | 2003-12-08 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize dengue virus |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007021672A2 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| CU23632A1 (es) | 2006-04-28 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales. |
| DK2257624T5 (da) | 2008-02-05 | 2012-09-10 | Medical Res Council | Fremgangsmåder og sammensætninger |
| KR20110061624A (ko) * | 2008-10-05 | 2011-06-09 | 더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티 | Ｃ형 간염 항체 및 이의 용도 |
| NZ592054A (en) | 2008-10-13 | 2013-06-28 | Inst Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| JP2012511026A (ja) | 2008-12-05 | 2012-05-17 | エルパス・インコーポレイテッド | 抗脂抗体結晶構造を用いた抗体設計 |
| WO2010093335A1 (en) | 2009-02-10 | 2010-08-19 | Nanyang Technological University | Antibodies for diagnosis and treatment of flaviviral infections |
| EP2353609A1 (en) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunization compositions and methods |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| US20140349321A1 (en) | 2011-12-16 | 2014-11-27 | Agency For Science, Technology And Research | Binding molecules against dengue virus and uses thereof |
| US9556254B2 (en) * | 2012-05-14 | 2017-01-31 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Cross-reactive antibodies against dengue virus and uses thereof |
| KR102165384B1 (ko) * | 2012-08-07 | 2020-10-16 | 메사추세츠 인스티튜트 오브 테크놀로지 | 항-뎅기 바이러스 항체 및 이들의 용도 |
| CA3212977A1 (en) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
| CA2938495A1 (en) * | 2014-02-11 | 2015-08-20 | Massachusetts Institute Of Technology | Full spectrum anti-dengue antibody |
-
2015
- 2015-02-11 CA CA2938495A patent/CA2938495A1/en active Pending
- 2015-02-11 SG SG10201807826XA patent/SG10201807826XA/en unknown
- 2015-02-11 EP EP15749661.3A patent/EP3104888A4/en not_active Withdrawn
- 2015-02-11 JP JP2016550573A patent/JP6707455B2/ja active Active
- 2015-02-11 BR BR112016017764A patent/BR112016017764A2/pt not_active Application Discontinuation
- 2015-02-11 SG SG11201606163QA patent/SG11201606163QA/en unknown
- 2015-02-11 KR KR1020167024129A patent/KR20160119806A/ko not_active Ceased
- 2015-02-11 US US14/620,144 patent/US9902764B2/en active Active
- 2015-02-11 WO PCT/US2015/015510 patent/WO2015123362A1/en not_active Ceased
- 2015-02-11 MX MX2016009991A patent/MX375402B/es active IP Right Grant
- 2015-02-11 AU AU2015217149A patent/AU2015217149B2/en active Active
- 2015-02-11 CN CN201580008265.9A patent/CN106413749B/zh active Active
-
2016
- 2016-07-14 IL IL246788A patent/IL246788A0/en unknown
-
2018
- 2018-01-11 US US15/868,328 patent/US10519220B2/en active Active
-
2019
- 2019-12-26 US US16/727,561 patent/US11421018B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507131A5 (enExample) | ||
| JP2020522261A5 (enExample) | ||
| JP2016529882A5 (enExample) | ||
| JP2017501711A5 (enExample) | ||
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2015503909A5 (enExample) | ||
| JP2015525795A5 (enExample) | ||
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| JP2018502060A5 (enExample) | ||
| IL261666B1 (en) | Binding proteins and methods of use thereof | |
| JP2018508188A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2010536384A5 (enExample) | ||
| JP2017505121A5 (enExample) | ||
| JP2014534806A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| JP2019505527A5 (enExample) | ||
| JP2021500916A5 (enExample) | ||
| JP2017537082A5 (enExample) | ||
| JP2005528914A5 (enExample) | ||
| JP2020515277A5 (enExample) | ||
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| JP2013508292A5 (enExample) | ||
| JP2016501877A5 (enExample) |